AnaptysBio Receives $40,000,000 Series D Funding

  • Feed Type
  • Date
    7/16/2015
  • Company Name
    AnaptysBio
  • Mailing Address
    10421 Pacific Center Court San Diego, CA 92121 USA
  • Company Description
    Founded in 2005, AnaptysBio is a privately-held therapeutic antibody company and the leader in the use of somatic hypermutation, or SHM, for antibody discovery and optimization. SHM is the body’s natural process for generating potent antibodies to fight disease.
  • Website
    http://www.anaptysbio.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $40,000,000
  • Transaction Round
    Series D
  • Proceeds Purposes
    Proceeds from the financing are intended to advance AnaptysBio’s first-in-class anti-IL-33 and anti-IL-36 receptor antibody programs through key Phase II studies. The financing will also support the continued discovery of novel therapeutic antibodies against emerging target biology in inflammation and immuno-oncology using AnaptysBio’s proprietary somatic hypermutation-based antibody discovery platform.
  • M&A Terms
  • Venture Investor
    BVF Partners
  • Venture Investor
    BioMed Ventures
  • Venture Investor
    Cormorant Asset Management
  • Venture Investor
    Frazier Healthcare Ventures
  • Venture Investor
    HBM Bioventures
  • Venture Investor
    Undisclosed
  • Venture Investor
    Novo Ventures

Trending on Xconomy